345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Media Investors Zimmer Biomet Announces First Quarter 2024 Financial Results (WARSAW, IN) May 2, 2024 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2024. The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over ...

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.88 per share, reflecting a decline of 0.5% compared to the same period last year. Revenues are forecasted to be $1.87 billion, representing a year-over-year increase of 2.2%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during th ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Zimmer Biomet (ZBH) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.This orthopedic device maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.05%.For the last reported quarter, Zimmer came o ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report first-quarter 2024 results on May 2, before market open.In the last reported quarter, the company’s earnings of $2.20 exceeded the Zacks Consensus Estimate by 2.3%. Over the trailing four quarters, its earnings outperformed the consensus estimate on three occasions and matched the same once, the average beat being 4.99%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayLike its industry competitors, Zimmer Biome ...

-- Zimmer Biomet Brings Joint Health Education and the Importance of Movement to America's Fastest-Growing Sport, Engaging the 48.3 Million Players, Fans of the Sport, and Raising Awareness as a Trusted Partner for Joint Replacement-- WARSAW, Ind., April 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced partnerships with three top pickleball organizations in the United States, becoming the first and only medical device partner for t ...

WARSAW, Ind., April 3, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Thursday, May 2, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

Financial Performance - In 2023, the company's net sales increased by 6.5% to $7,394.2 million compared to 2022, with a negative impact of 1.0% from foreign currency exchange rates [169][174]. - Net earnings from continuing operations rose significantly to $1,024.0 million in 2023, up from $290.2 million in 2022, driven by higher net sales and lower operating expenses [170]. - The company expects mid-single digit revenue growth in 2024, with a projected negative impact of approximately 0.5% from foreign currency exchange rates [171]. - In the U.S., net sales grew by 6.9% to $4,288.8 million in 2023, while international sales increased by 6.1% to $3,105.4 million [174][179]. - The company's Knees product category saw a 9.4% increase in net sales to $3,038.4 million, while Hips increased by 3.8% to $1,967.2 million in 2023 [175][180]. - Demand trends contributed positively with an 8.1% increase in volume and mix of product sales in 2023, aided by the recovery of elective surgical procedures [176]. - Global selling prices negatively impacted sales by 0.6% in 2023, reflecting ongoing pricing pressure from healthcare systems [177]. Operating Efficiency - Operating profit margin improved to 17.3% in 2023, up from 10.0% in 2022, due to higher net sales and lower litigation-related charges [181]. - Research and development expenses increased to 6.2% of net sales in 2023, driven by higher personnel costs and compliance spending [186]. - The gross margin percentage improved to 64.2% in 2023, up from 63.3% in 2022, despite lower average selling prices [185]. - Selling, general & administrative (SG&A) expenses increased in amount but decreased as a percentage of net sales in 2023 compared to 2022 [187]. - The company recognized expenses of $151.9 million related to restructuring plans in 2023, down from $191.6 million in 2022 [189]. Cash Flow and Liquidity - Cash flows provided by operating activities from continuing operations were $1,581.6 million in 2023, an increase from $1,356.2 million in 2022 [204]. - Cash flows used in investing activities from continuing operations were $778.9 million in 2023, compared to $522.0 million in 2022, including $134.9 million related to acquisitions [205]. - As of December 31, 2023, the company had $415.8 million in cash and cash equivalents and $1.0 billion available to borrow under a 364-day revolving credit agreement [202]. Tax and Restructuring - The effective tax rate (ETR) on earnings from continuing operations was 4.0% in 2023, down from 27.9% in 2022, primarily due to unrecognized tax benefits [194]. - The company expects to reduce gross annual pre-tax operating expenses by $175 million to $200 million relative to the 2023 baseline expenses by the end of 2025 as part of the 2023 Restructuring Plan [213]. Regional Performance - Operating profit in the Americas increased in 2023, driven by higher net sales from the recovery of elective surgical procedures and new product introductions [198]. - In EMEA, operating profit and operating profit as a percentage of net sales increased in 2023 due to higher net sales and improved pricing [199]. - In Asia Pacific, operating profit increased despite a decline in net sales due to foreign currency exchange rates, offset by higher hedge gains [201]. Legal and Compliance - Total liabilities for litigation matters estimated at $244.1 million as of December 31, 2023, expected to be paid over the next few years [216]. - Future payments from development and distribution agreements could range from $0 to $440 million depending on product R&D and sales milestones [217]. - The company had net assets in legal entities with non-U.S. Dollar functional currencies amounting to $1,854.5 million as of December 31, 2023 [234]. - The company is involved in various ongoing legal proceedings and establishes liabilities for loss contingencies when probable losses can be reasonably estimated [224]. Risk Management - A sensitivity analysis indicated that a 10% change in foreign currency exchange rates could affect earnings by approximately $114 million to $105 million before income taxes through June 2026 [232]. - The majority of the company's debt is fixed-rate, and a 10% change in interest rates would not materially affect interest expense [240]. - The company is exposed to credit risk primarily from cash and cash equivalents, derivative instruments, and accounts receivable, but believes reserves for losses are adequate [241]. - The company evaluates the carrying value of goodwill and intangible assets annually, with two reporting units exceeding their carrying values by more than 50% during the latest testing [227]. - The company enters into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price risks [237]. - Management regularly assesses the need for changes to the net realizable values of inventory based on market conditions and demand patterns [219].

The ROSA® Shoulder System Becomes the First-to-Market Robotic Surgical Assistant for Shoulder Arthroplasty and the Fourth ROSA Robotics Application in Five Years WARSAW, Ind., Feb. 22, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world's first robotic surgery system for shoul ...

Zimmer Biomet (ZBH) is likely to grow in the coming quarters, backed by the implementation of meaningful strategic pillars within its Knee business. The company is benefitting from improved procedural volumes in a gradually stabilizing global musculoskeletal market. Zimmer Biomet is also bolstering its foothold in emerging markets for long-term growth opportunities, buoying optimism.Meanwhile, unfavorable solvency and an intense competitive landscape remain concerning for the company.In the past year, this ...